BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
How a seabird native to Hawaii has adapted to life in Honolulu's concrete jungle - 2Moon milestones: A rundown of Artemis 2's many spaceflight firsts
- 36 Hints to Upgrade Your Charm, In addition to Your Mentality
- 4Death toll from floods in Afghanistan rises to 61
- 5Savvy Watches: Which One Is Appropriate for You?
- Overhaul Your Rest: Tips for a Serene Evening
- Council removes proposal to rename park named after former president of Israel
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- Find the Mysteries of Effective Objective Setting: Transforming Dreams into Feasible Targets
- Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
- Partner of crime boss Steven Lyons arrested in Dubai
- Which European countries have mandatory or voluntary military service
- German police 'cleared path for fascists with batons,' protesters say
- More Than 110 New Species Discovered In Deep Waters Off Australia
